PI3K-IN-35

PI3K-IN-35 (Compound 6l) is a highly selective PI3K inhibitor with IC50 values of 13.98, 7.22 and 10.94 μM for PI3K-α、PI3K-β and PI3K-δ, respectively. PI3K-IN-35 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-35 can be used in leukemia research[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Signaling Pathways >> PI3K/Akt/mTOR >> PI3K

PI3Kα:13.98 μM (IC50)

PI3Kβ:7.22 μM (IC50)

PI3Kδ:10.94 μM (IC50)

PI3K-IN-35 (Compound 6l) (10 μM, 48 hours) possess potent antiproliferative activity can inhibit proliferation of Leukemia SR cell lines in vitro[1]. PI3K-IN-35 (Compound 6l) induces cell cycle arrest toward the G2-M phase (41.61%) and leads to DNA synthesis and apoptosis[1]. PI3K-IN-35 (Compound 6l) (10 μM, 48 hours) results in apoptotic with 16.98% of cells in the early and latest age[1]. Cell Cytotoxicity Assay[1] Cell Line: Leukemia SR cell lines. Concentration: 10 μM Incubation Time: 48 hours Result: Antiproliferative activity with values of 13.59 μM.

[1]. Helwa AA, et al. Novel antiproliferative agents bearing morpholinopyrimidine scaffold as PI3K inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorg Chem. 2020 Sep;102:104051.